Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)

分析 ECOG-ACRIN 不良事件数据，以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略

• 批准号: 10240648
• 负责人: ROBERT J GRAY
• 金额: $ 58.95万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-18 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10240648
• 关键词: Adverse effects; Adverse event; Advocate; American College of Radiology Imaging Network; Aromatase Inhibitors; Cancer Survivor; Chronic; Classification; Clinical; Clinical Trials; Collaborations; Common Terminology Criteria for Adverse Events; Complex; Data; Decision Making; Demographic Factors; Development; Disease; Dose; Drug Side Effects; Early treatment; Eastern Cooperative Oncology Group; Equilibrium; Frequencies; Immunotherapy; Individual; Insurance Coverage; Lead; Measurement; Methodology; Methods; Modeling; Modification; Monitor; Nature; Oral; Patient Outcomes Assessments; Patients; Pharmaceutical Preparations; Phenotype; Positioning Attribute; Predictive Value; Provider; Race; Reporting; Research; Risk; Sampling; Severities; Standardization; Supportive care; Symptoms; Therapeutic; Therapeutic Trials; Time; Treatment Protocols; Treatment outcome; Woman; anticancer research; base; cancer therapy; comorbidity; expectation; experience; improved; indexing; individual patient; innovation; longitudinal analysis; malignant breast neoplasm; novel; patient oriented; public health relevance; recruit; side effect; targeted agent; targeted treatment; treatment adherence; treatment risk; treatment strategy; willingness

Project Summary EVOLV proposes to deliver sophisticated and standardized methods for assessing, monitoring, analyzing, and reporting adverse events (AEs) experienced by individuals undergoing cancer treatment. These methods will harness the potential of the patient-reported outcomes version of the NCI Common Terminology Criteria for Adverse Events (PRO-CTCAETM) to provide previously unavailable patient perspectives on the tolerability of treatments (including targeted agents, immunotherapies, and other evolving treatments for which the type, severity, timing, and trajectory of adverse events is less known). Such information will help providers better identify and support patients at risk for treatment discontinuation, dose reductions, and treatment delays. Specifically, this study aims to: 1) perform longitudinal analyses of CTCAE and PRO-CTCAE data from trials conducted within the ECOG-ACRIN Cancer Research Group, using traditional and innovative strategies to examine AE trajectories and to produce a new reporting standard that reflects severity and fluctuations over time; 2) examine PRO-CTCAE and CTCAE predictors of treatment adherence and discontinuation; and 3) validate the broader predictive value of GP5, a single item from the Functional Assessment of Cancer Therapy- General (FACT-G) shown to predict early treatment discontinuation among women with breast cancer taking aromatase inhibitors. The study will also explore two novel measurement models for PRO-CTCAE scores and CTCAE grades: a phenotypic model including co-occurrence of symptoms and a cumulative burden index (CBI) for characterizing the quantity of burden accumulated by patients over time. Analyses will include demographic factors and insurance status to identify potential disparities.

项目总结